← back to search

Anat Gafter‐Gvili

Tel Aviv University · IL
Area of research
Pathology and Forensic Medicine · Hematology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Neutropenia and Cancer Infections, and Erythropoietin and Anemia Treatment.
h-index
55
citations
10,313
works
344
NIH funding
primary concept
Medicine
email

Recent publications

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting– a retrospective study
Annals of Hematology 2025cited by 7position: middledoi
The utility of inpatient work-up of incidental anemia during hospitalization for an acute medical condition: A retrospective cohort study.
2025cited by 0position: contributordoi
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Nature Medicine 2024cited by 235position: middledoi
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.
2024cited by 190position: contributordoi
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
Annals of Hematology 2023cited by 6position: middledoi
Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study
Blood 2023cited by 2position: middledoi
Effect of steroid treatment on the diagnostic yield of baseline <sup>18</sup>f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma.
2022cited by 5position: contributordoi
The yield of F<sup>18</sup> FDG PET-CT for the investigation of fever of unknown origin, compared with diagnostic CT.
2021cited by 24position: contributordoi
Venous Thromboembolism Prophylaxis in Acute Medically Ill Patients: A Retrospective Cohort Study
The American Journal of Medicine 2020cited by 9position: contributordoi
Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome
Hematological Oncology 2018cited by 100position: lastdoi
Medication‐induced SIADH: distribution and characterization according to medication class
British Journal of Clinical Pharmacology 2017cited by 97position: lastdoi
Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
European Journal of Cancer 2017cited by 60position: middledoi
Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?
Leukemia & lymphoma/Leukemia and lymphoma 2017cited by 3position: middledoi
On the safety of intravenous iron, evidence trumps conjecture
Haematologica 2015cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2020–2025)Pia Raanani · Tel Aviv University4 papers (2017–2025) · 4 papers (2017–2025) · 3 papers (2023–2025)Neta Goldschmidt · Hadassah Medical Center3 papers (2023–2025) · 3 papers (2017–2025)Boaz Nachmias · Hadassah Medical Center3 papers (2023–2025)Shlomzion Aumann · Hebrew University of Jerusalem3 papers (2023–2025)Chava Perry · Tel Aviv Sourasky Medical Center3 papers (2017–2025) · 2 papers (2023–2025)Hanna Bernstine · 2 papers (2021–2022) · 2 papers (2023–2025)Sebastian Theurich · Gene Therapy Laboratory2 papers (2024–2024) · 1 papers (2017–2017) · 1 papers (2015–2015)Chezi Ganzel · Soroka Medical Center1 papers (2017–2017)Mathias Witzens‐Harig · Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie1 papers (2017–2017)David M. Cordas dos Santos · Massachusetts Institute of Technology1 papers (2024–2024)Irit Avivi · Bristol-Myers Squibb (Switzerland)1 papers (2017–2017)Carmit Rubin · Sheba Medical Center1 papers (2017–2017)